Search research articles
Contact Us
Filters
Showing results (1-10 of 108) with videos related to
Page
of 11
Sort By:
Handbook of Experimental Pharmacology
|
August 31, 2021
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development
Jane V Aldrich, Jay P McLaughlin
Drug Discovery Today. Technologies
|
January 15, 2013
Opioid Peptides: Potential for Drug Development
Jane V Aldrich, Jay P McLaughlin
Neuroscience Letters
|
April 10, 2021
Mini review: Promotion of substance abuse in HIV patients: Biological mediation by HIV-1 Tat protein
Thomas J Cirino, Jay P McLaughlin
Current HIV Research
|
March 18, 2015
Contribution of HIV-Tat protein to HIV-sequelae (part 1)
Jay P McLaughlin, Jason J Paris
The AAPS Journal
|
May 12, 2009
Peptide kappa opioid receptor ligands: potential for drug development
Jane V Aldrich, Jay P McLaughlin
Current HIV Research
|
March 31, 2015
Contribution of HIV-Tat protein to HIV-sequelae
Jay P McLaughlin, Jason J Paris
Molecular Brain
|
August 8, 2022
Epigenetic signature of N-terminal acetyltransferases: a probable mediator of immune and neuropathogenesis in HIV infection
Vaishnavi Sundar, Jay P McLaughlin, Thangavel Samikkannu
Hormones and Behavior
|
April 15, 2014
Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS
Jason J Paris, Jason Fenwick, Jay P McLaughlin
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 5, 2003
Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses
Jay P McLaughlin, Monica Marton-Popovici, Charles Chavkin
Current HIV Research
|
January 24, 2015
Estrous cycle and HIV-1 Tat protein influence cocaine-conditioned place preference and induced locomotion of female mice
Jason J Paris, Jason Fenwick, Jay P McLaughlin
Page
of 11
Search research articles
Search
Showing results (1-10 of 108) with videos related to
Sort By:
Page
of 11
Handbook of Experimental Pharmacology
|
August 31, 2021
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development
Jane V Aldrich, Jay P McLaughlin
Drug Discovery Today. Technologies
|
January 15, 2013
Opioid Peptides: Potential for Drug Development
Jane V Aldrich, Jay P McLaughlin
Neuroscience Letters
|
April 10, 2021
Mini review: Promotion of substance abuse in HIV patients: Biological mediation by HIV-1 Tat protein
Thomas J Cirino, Jay P McLaughlin
Current HIV Research
|
March 18, 2015
Contribution of HIV-Tat protein to HIV-sequelae (part 1)
Jay P McLaughlin, Jason J Paris
The AAPS Journal
|
May 12, 2009
Peptide kappa opioid receptor ligands: potential for drug development
Jane V Aldrich, Jay P McLaughlin
Current HIV Research
|
March 31, 2015
Contribution of HIV-Tat protein to HIV-sequelae
Jay P McLaughlin, Jason J Paris
Molecular Brain
|
August 8, 2022
Epigenetic signature of N-terminal acetyltransferases: a probable mediator of immune and neuropathogenesis in HIV infection
Vaishnavi Sundar, Jay P McLaughlin, Thangavel Samikkannu
Hormones and Behavior
|
April 15, 2014
Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS
Jason J Paris, Jason Fenwick, Jay P McLaughlin
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 5, 2003
Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses
Jay P McLaughlin, Monica Marton-Popovici, Charles Chavkin
Current HIV Research
|
January 24, 2015
Estrous cycle and HIV-1 Tat protein influence cocaine-conditioned place preference and induced locomotion of female mice
Jason J Paris, Jason Fenwick, Jay P McLaughlin
Page
of 11